|
Apr 15
|
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
|
|
Apr 4
|
Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%
|
|
Mar 31
|
Bio-Techne Opens New Customer Experience Centre in Germany
|
|
Mar 31
|
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
|
|
Feb 26
|
Bio-Rad (BIO) International Revenue Performance Explored
|
|
Feb 25
|
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
|
|
Feb 25
|
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
|
|
Feb 18
|
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
|
|
Feb 18
|
BIO Stock Might Rise Following the Offer to Acquire Stilla
|
|
Feb 17
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Feb 15
|
Bio-Rad price target lowered to $447 from $477 at RBC Capital
|
|
Feb 15
|
Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 14
|
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
|
|
Feb 14
|
Bio-Rad set to acquire Stilla Technologies
|
|
Feb 14
|
Q4 2024 Bio Rad Laboratories Inc Earnings Call
|
|
Feb 14
|
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
|
|
Feb 14
|
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
|
|
Feb 13
|
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
|
|
Feb 13
|
Bio-Rad: Q4 Earnings Snapshot
|
|
Feb 13
|
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
|